Navigation path

Additional tools

    Profile of registrant

F. Hoffmann-La Roche Ltd.

Identification number in the register: 18940431725-51
Registration date: 20/05/2009 10:57:35

The information on this entity was last modified on: 02/05/2014 11:14:00
The date of the last annual update was: 02/05/2014 11:14:00

This entry follows the format of the previous Register. It will be changed to the new format when the entity makes the next update.
Next update due latest on: 27/04/2015

    Registrant : Organisation or self-employed individual

F. Hoffmann-La Roche Ltd.



    Section of registration

II - In-house lobbyists and trade/professional associations

Companies & groups

    Contact details

Grenzacherstrasse, 124
Basel 4070

(+41) 61 688 11 11


    Person with legal responsibility

Mr  Severin Schwan


    Person in charge of EU relations

Nathalie Stieger

Head of Government Affairs

    Goals / remit

Headquartered in Basel, Switzerland, Roche is a leader in research-focused healthcare with combined strengths in pharmaceuticals and diagnostics. Roche is the world’s largest biotech company, with truly differentiated medicines in oncology, immunology, infectious diseases, ophthalmology and neuroscience. Roche is also the world leader in in vitro diagnostics and tissue-based cancer diagnostics, and a frontrunner in diabetes management. Roche’s personalised healthcare strategy aims at providing medicines and diagnostics that enable tangible improvements in the health, quality of life and survival of patients. Founded in 1896, Roche has been making important contributions to global health for more than a century. Twenty-four medicines developed by Roche are included in the WHO Model Lists of Essential Medicines, among them life-saving antibiotics, antimalarials and chemotherapy.

In 2013 the Roche Group employed over 85,000 people worldwide, invested 8.7 billion Swiss francs in R&D and posted sales of 46.8 billion Swiss francs. Genentech, in the United States, is a wholly owned member of the Roche Group. Roche is the majority shareholder in Chugai Pharmaceutical, Japan. For more information, please visit



- Interactions (direct contacts) with EU Institutions relating to legislation, and implementation of EU regulation at national level;
- Inputting EU Institutions open consultation, including participation in events sponsored by EU Institutions;
- Organisation / sponsoring of information meetings, involving EU Institutions;
- Improve patient safety and strengthen disease prevention in Europe;
- Increase Europe’s competitiveness as a location for Research and Development investment;
- Pharmaceuticals, Diagnostics, Diabetes Care, Intellectual Property, Trade

    Number of persons involved in the activities described in the box above


    Persons accredited for access to European Parliament premises

First name Surname Start Date End Date
Sabine Atzor 06/08/2014 04/08/2015
Nathalie STIEGER 19/06/2014 17/06/2015

    Fields of interest

  • Consumer Affairs
  • Development
  • Enterprise
  • Environment
  • Internal Market
  • Public Health
  • Research and Technology
  • Trade

    Membership and affiliation

Roche is a member of EFPIA, EBE, EDMA, EPPOSI, Kangaroo Group.

    Financial data

01/2013  -  12/2013

450,000  € - 500,000  €

0 €

0 €

This estimate is based on the EU Lobbying activities undertaken by various experts within the company as Roche does not have an EU Public Affairs office in Brussels.

    Code of conduct

By its registration the organisation has signed the Transparency Register Code of Conduct.

The organisation has also declared to be bound to the following other Code:
Roche Code of Conduct